What is the recommended dosing and administration schedule for encorafenib (300 mg orally daily), panitumumab (6 mg/kg IV), and mFOLFOX6 in a patient with hepatic flexure adenocarcinoma that is KRAS/NRAS wild‑type and BRAF V600E mutant?

Encorafenib + Panitumumab + mFOLFOX6 for BRAF V600E-Mutant Hepatic Flexure Adenocarcinoma

For BRAF V600E-mutant, RAS wild-type metastatic colorectal cancer of the hepatic flexure, administer encorafenib 300 mg orally once daily continuously, panitumumab 6 mg/kg IV every 14 days, and standard mFOLFOX6 chemotherapy. This triplet regimen represents the FDA-approved standard of care based on the BREAKWATER trial, which demonstrated superior outcomes compared to chemotherapy alone 1, 2, 3.

Dosing Schedule

Encorafenib

• 300 mg orally once daily (continuously, every day)
• Take with or without food
• Continue throughout treatment until disease progression or unacceptable toxicity 1

Panitumumab

• 6 mg/kg IV every 14 days (biweekly)
• Infusion time: 60 minutes if dose ≤1000 mg, or 90 minutes if dose >1000 mg
• Administer on Day 1 of each 14-day cycle 2

mFOLFOX6

• Standard dosing administered every 14 days:
  • Oxaliplatin 85 mg/m² IV over 2 hours
  • Leucovorin 400 mg/m² IV over 2 hours
  • 5-FU 400 mg/m² IV bolus, then 2400 mg/m² IV continuous infusion over 46-48 hours
• Given on Day 1 of each 14-day cycle 1

Critical Pre-Treatment Requirements

Confirm BRAF V600E mutation status in tumor or plasma specimens using an FDA-approved test before initiating encorafenib 1. Confirm RAS wild-type status (both KRAS and NRAS wild-type) before initiating panitumumab, as panitumumab is contraindicated and potentially harmful in RAS-mutant disease 4, 2.

Evidence Supporting This Regimen

The BREAKWATER phase III trial demonstrated that encorafenib + cetuximab + mFOLFOX6 significantly improved outcomes in first-line BRAF V600E-mutant mCRC 3:

• Median progression-free survival: 12.8 months versus 7.1 months (HR 0.53, P<0.001)
• Median overall survival: 30.3 months versus 15.1 months (HR 0.49, P<0.001)
• Objective response rate: significantly superior to standard chemotherapy

While the BREAKWATER trial used cetuximab, panitumumab is an acceptable alternative anti-EGFR antibody with similar mechanism of action. The FDA label explicitly approves encorafenib 300 mg daily with either cetuximab or panitumumab plus FOLFOX/FOLFIRI for BRAF V600E-mutant colorectal cancer 1.

Key Monitoring and Management

Dermatologic Toxicity (Most Common)

• Monitor closely: 90% of patients experience dermatologic reactions with panitumumab; 15% are severe 2
• Expect acneiform rash, paronychia, dry skin, pruritus
• Dose modifications for panitumumab: Reduce infusion rate by 50% for Grade 1-2 reactions; withhold for Grade 3 reactions until improved to ≤Grade 2, then resume at 50% dose; permanently discontinue for Grade 4 or third occurrence of Grade 3 2
• Limit sun exposure and use sun protection

Electrolyte Depletion

• Monitor magnesium, potassium, and calcium closely throughout treatment
• Hypomagnesemia and hypokalemia occur in >20% of patients on panitumumab + FOLFOX 2
• Institute aggressive electrolyte replacement as needed

Hematologic Toxicity

• Expect neutropenia, anemia, thrombocytopenia from mFOLFOX6
• Monitor CBC with differential before each cycle
• Dose reduce or delay chemotherapy per standard FOLFOX guidelines

Hepatotoxicity

• Monitor liver function tests, particularly with hepatic metastases
• Recent case reports demonstrate successful treatment even with baseline liver dysfunction, with rapid normalization of liver enzymes after cycle 1 5

Infusion Reactions (Panitumumab)

• Reduce infusion rate by 50% for mild-to-moderate reactions
• Terminate infusion permanently for severe reactions 2

Gastrointestinal Toxicity

• Diarrhea, stomatitis, nausea common (>20% incidence)
• Provide aggressive supportive care and antiemetics

Treatment Duration and Maintenance

Continue the triplet regimen for up to 12 cycles or until disease progression, then consider maintenance therapy with encorafenib + panitumumab (without chemotherapy) 3, 5. This approach balances efficacy with cumulative oxaliplatin neurotoxicity.

Special Considerations for Hepatic Flexure Location

The hepatic flexure is anatomically right-sided. Right-sided primary tumors with RAS wild-type status generally have inferior outcomes with anti-EGFR therapy compared to left-sided tumors 6. However, in BRAF V600E-mutant disease, the addition of BRAF inhibition (encorafenib) to anti-EGFR therapy overcomes this limitation and provides substantial benefit regardless of primary tumor location 3.

Common Pitfalls to Avoid

1. Do not use panitumumab if any RAS mutation is present (KRAS or NRAS, any exon) - it is harmful and contraindicated 4, 2
2. Do not use encorafenib 450 mg daily - the colorectal cancer dose is 300 mg daily, not the melanoma dose 1
3. Do not delay treatment for mild liver dysfunction - recent evidence shows rapid improvement with treatment initiation 5
4. Do not omit the BRAF inhibitor - anti-EGFR therapy alone is insufficient for BRAF-mutant disease 7